Novacyt
S.A.
("Novacyt", the "Company" or
the "Group")
Directorate
changes and full year 2023 results update
Lyn Rees
appointed CEO
Dr. Joanne
Mason, CSO, to join the Board
Paris, France, and Eastleigh and Manchester,
UK - 11 April 2024 - Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM:
NCYT), an international molecular diagnostics company with a broad
portfolio of integrated technologies and services, announces
changes to the Board of Directors. Lyn Rees, Executive Director,
has been appointed Chief Executive Officer and James McCarthy will
step down from the Board as Acting CEO, both effective from 1 May
2024. James will remain with the Company for a period of time to
officiate a smooth transition.
Lyn is a seasoned
healthcare executive with over 28 years' global leadership and
commercial experience and a proven track record of successfully
building/scaling companies. He became CEO of Yourgene Health plc in
2018 where he led the group through four acquisitions and the sale
to Novacyt in 2023. Prior to this, he spent 19 years at British
Biocell International (now BBI Group), nine of which as Group CEO,
where he completed and successfully integrated seven
acquisitions.
Additionally, Dr
Joanne Mason, the Company's Chief Scientific Officer, will join the
Novacyt Board as an Executive Director effective from 1 May 2024
subject to shareholder approval at the Company's Annual General
Meeting and, Dr Andrew Health, Non-Executive Director will retire
from the Board of Directors effective 1 May 2024.
Joanne is a
leading molecular biologist, with over 22 years' experience having
worked in senior positions both in industry and at prominent
research institutes. As Chief Scientific Officer at Yourgene
Health, she led the development of next generation molecular
diagnostics. Prior to this, she held lead scientific roles at
Cambridge Epigenetix, Genomics England and Oxford Biomedical
Research Centre. She has also acted as an adviser on a number of
boards and committees, including the DOH Rare Disease Policy board,
MHRA Genomics for Diagnosis forum and UK NEQA. Joanne holds a
PhD from the University of Cambridge in Molecular and Cellular
Biology.
Commenting, James Wakefield,
Non-Executive Chairman, said: "On behalf of the Board I would like to
thank James and Andrew for their hard work and significant
contribution to the Group, and wish them both well in their future
endeavours. We are delighted to welcome Jo to the Board and Lyn as
CEO - they have been instrumental in the seamless integration of
Novacyt and Yourgene and will be key drivers in the accelerated
growth of the enlarged Group portfolio. Lyn has significant global
leadership and commercial expertise, and I am confident that he is
the right person to lead the Group as it continues to execute its
growth strategy and generate value for
shareholders."
Commenting, Lyn Rees, Executive
Director and incoming CEO, said: "I am excited to have the
opportunity to lead Novacyt in its next stage of development. The
molecular diagnostics market is experiencing rapid growth, driven
by the continued demand for fast and accurate diagnostics and with
our strong portfolio of molecular assays and instruments combined
with our leading expertise I believe we are well placed to capture
this. I would like to thank James for his support since I joined
the Company and look forward to working with the entire team as we
continue to deliver our strategy."
FY23 Results Update
Under Euronext
Growth reporting requirements, the Company is required to publish
its annual accounts within four months of its year-end.
The publication of
the annual results for the year ended 31 December 2023, initially
scheduled for release by 30 April 2024, has been postponed and will
be published by the end of May 2024. This is due to the time
required to integrate the accounts of Yourgene Health, acquired
towards the end of the year, into Novacyt's consolidated
results.
Unaudited revenue
for FY23 remains in line with the prior guidance at
£11.6m.
Further information on Dr Joanne
Mason
Dr Joanne Nicola
Mason (née Gooch) (aged 49) has held the following directorships or
partnerships in the past five years:
|
Current
directorships/partnerships
|
Previous directorships/partnerships (last
five years)
|
|
Yourgene Genomic Services Ltd
Yourgene Health UK Ltd
|
Yourgene Health Limited (formerly Yourgene
Health plc)
|
Dr
Mason does not hold any shares in the Company.
Contacts
|
Novacyt SA
|
https://novacyt.com/investors
|
|
James
McCarthy, Acting Chief Executive Officer
|
Via Walbrook PR
|
|
Steve
Gibson, Chief Financial Officer
|
|
|
SP Angel Corporate Finance LLP
(Nominated Adviser and Broker)
|
+44 (0)20 3470 0470
|
|
Matthew
Johnson / Charlie Bouverat (Corporate Finance)
Vadim
Alexandre / Rob Rees (Corporate Broking)
|
|
|
|
|
|
Deutsche Numis
(Joint Broker)
|
+44 (0)20 7260 1000
|
|
Freddie
Barnfield / Duncan Monteith / Michael Palser
|
|
|
|
|
|
Allegra Finance (French Listing
Sponsor)
Rémi
Durgetto / Yannick Petit
|
+33 (1) 42 22 10 10
r.durgetto@allegrafinance.com
/ y.petit@allegrafinance.com
|
|
|
|
|
Walbrook PR (Financial PR &
IR)
Stephanie Cuthbert / Paul McManus
/
Phillip
Marriage / Alice Woodings
|
+44 (0)20 7933 8780 or novacyt@walbrookpr.com
+44 (0)7796 794 663 / +44 (0)7980 541
893
+44 (0)7867 984 082 / +44 (0)7407 804
654
|
|
|
|
|
| |
About Novacyt Group (www.novacyt.com)
Novacyt is an international
molecular diagnostics company providing a broad portfolio of
integrated technologies and services, primarily focused on the
delivery of genomic medicine. The Company develops, manufactures, and commercialises a range of
molecular assays and instrumentation to deliver workflows and
services that enable seamless end-to-end solutions from sample to
result across multiple sectors including human health, animal
health and environmental.
The Company is divided into three
business segments:
|
Clinical
|
Broad portfolio of human clinical in vitro diagnostic products,
workflows and services focused on three therapeutic areas:
·
Reproductive Health: NIPT, Cystic Fibrosis and
other rapid aneuploidy tests
·
Precision Medicine: DPYD genotyping
assay
·
Infectious Diseases: Winterplex, multiplex winter
respiratory PCR panel
|
|
Instrumentation
|
Portfolio of next generation size selection DNA
sample preparation platforms and rapid PCR
machines, including:
·
Ranger® Technology: automated DNA sample
preparation and target enrichment technology
MyGo: real-time quantitative PCR
(qPCR) instruments
|
|
Research Use Only
|
Range of services for the research industry:
· Design,
manufacture, and supply of high-performance qPCR assays and
workflows for use in human health, agriculture, veterinary and
environmental, to support global health organisations and the
research industry
·
Pharmaceutical research services: whole genome sequencing (WGS) /
whole exome sequencing (WES)
|
Novacyt is headquartered in Vélizy
in France with offices in the UK (in Stokesley, Eastleigh and
Manchester), Taipei, Singapore, the US and Canada and has a
commercial presence in over 65 countries. The Company is listed on
the London Stock Exchange's AIM market ("NCYT") and on the Paris
Stock Exchange Euronext Growth ("ALNOV").
For more information, please refer
to the website: www.novacyt.com
